183 related articles for article (PubMed ID: 23509157)
1. β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis.
Oellerich T; Oellerich MF; Engelke M; Münch S; Mohr S; Nimz M; Hsiao HH; Corso J; Zhang J; Bohnenberger H; Berg T; Rieger MA; Wienands J; Bug G; Brandts C; Urlaub H; Serve H
Blood; 2013 May; 121(19):3889-99, S1-66. PubMed ID: 23509157
[TBL] [Abstract][Full Text] [Related]
2. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
3. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
4. SYK regulates mTOR signaling in AML.
Carnevale J; Ross L; Puissant A; Banerji V; Stone RM; DeAngelo DJ; Ross KN; Stegmaier K
Leukemia; 2013 Nov; 27(11):2118-28. PubMed ID: 23535559
[TBL] [Abstract][Full Text] [Related]
5. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.
Boros K; Puissant A; Back M; Alexe G; Bassil CF; Sinha P; Tholouli E; Stegmaier K; Byers RJ; Rodig SJ
Oncotarget; 2015 Sep; 6(28):25575-87. PubMed ID: 26315286
[TBL] [Abstract][Full Text] [Related]
6. Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice.
Sprissler C; Belenki D; Maurer H; Aumann K; Pfeifer D; Klein C; Müller TA; Kissel S; Hülsdünker J; Alexandrovski J; Brummer T; Jumaa H; Duyster J; Dierks C
Blood Cancer J; 2014 Aug; 4(8):e240. PubMed ID: 25148222
[TBL] [Abstract][Full Text] [Related]
7. Proteomic and genetic approaches identify Syk as an AML target.
Hahn CK; Berchuck JE; Ross KN; Kakoza RM; Clauser K; Schinzel AC; Ross L; Galinsky I; Davis TN; Silver SJ; Root DE; Stone RM; DeAngelo DJ; Carroll M; Hahn WC; Carr SA; Golub TR; Kung AL; Stegmaier K
Cancer Cell; 2009 Oct; 16(4):281-94. PubMed ID: 19800574
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
Spiekermann K; Pau M; Schwab R; Schmieja K; Franzrahe S; Hiddemann W
Exp Hematol; 2002 Mar; 30(3):262-71. PubMed ID: 11882364
[TBL] [Abstract][Full Text] [Related]
9. Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia.
Long X; Yu Y; Perlaky L; Man TK; Redell MS
Br J Haematol; 2015 Sep; 170(5):704-18. PubMed ID: 25974135
[TBL] [Abstract][Full Text] [Related]
10. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
11. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
[TBL] [Abstract][Full Text] [Related]
12. Constitutive activation of STAT transcription factors in acute myelogenous leukemia.
Spiekermann K; Biethahn S; Wilde S; Hiddemann W; Alves F
Eur J Haematol; 2001 Aug; 67(2):63-71. PubMed ID: 11722592
[TBL] [Abstract][Full Text] [Related]
13. FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation.
Oellerich T; Mohr S; Corso J; Beck J; Döbele C; Braun H; Cremer A; Münch S; Wicht J; Oellerich MF; Bug G; Bohnenberger H; Perske C; Schütz E; Urlaub H; Serve H
Blood; 2015 Mar; 125(12):1936-47. PubMed ID: 25605370
[TBL] [Abstract][Full Text] [Related]
14. Can treating the SYK cell cure leukemia?
Downing JR
Cancer Cell; 2009 Oct; 16(4):270-1. PubMed ID: 19800569
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation.
Wetzler M; Brady MT; Tracy E; Li ZR; Donohue KA; O'Loughlin KL; Cheng Y; Mortazavi A; McDonald AA; Kunapuli P; Wallace PK; Baer MR; Cowell JK; Baumann H
Clin Cancer Res; 2006 Nov; 12(22):6817-25. PubMed ID: 17121903
[TBL] [Abstract][Full Text] [Related]
16. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress.
Uckun FM; Qazi S; Ma H; Tuel-Ahlgren L; Ozer Z
Proc Natl Acad Sci U S A; 2010 Feb; 107(7):2902-7. PubMed ID: 20133729
[TBL] [Abstract][Full Text] [Related]
17. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
18. Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia.
Bartaula-Brevik S; Lindstad Brattås MK; Tvedt THA; Reikvam H; Bruserud Ø
Expert Opin Investig Drugs; 2018 Apr; 27(4):377-387. PubMed ID: 29611449
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
[TBL] [Abstract][Full Text] [Related]
20. Pyk2 and Syk participate in functional activation of granulocytic HL-60 cells in a different manner.
Miura Y; Tohyama Y; Hishita T; Lala A; De Nardin E; Yoshida Y; Yamamura H; Uchiyama T; Tohyama K
Blood; 2000 Sep; 96(5):1733-9. PubMed ID: 10961871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]